Efficacy and Safety of GTx-024 in Patients With Estrogen Receptor (ER)+/Androgen Receptor (AR)+ Breast Cancer
Status:
Completed
Trial end date:
2019-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if GTx-024 at different dosages (9 mg or 18 mg) is
effective and safe in the treatment of patients with metastatic or locally advanced Estrogen
Receptor (ER)+ and Androgen Receptor (AR)+ breast cancer in postmenopausal women.